1. Scrip
  2. >>Business
  3. >>Strategy

Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies

Founder Says $61m Financing Will Allow ‘Developmental Lift Off’

 
• By Sten Stovall

Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.   

Emerging Company Profile: Anjarium Biosciences
Anjarium Mission ‘To Correct Viral Gene Therapy Shortcomings’ • Source: Alamy

Four years after its launch, Swiss gene therapy pioneer Anjarium Biosciences AG has banked CHF55.5m ($61m) from a series A financing that will be used to develop innovative non-viral, tissue-targeted gene therapies that are optimized to improve patient outcomes in a range of serious genetic diseases. Its founder said that in the process, the firm would highlight the shortcomings of the current viral-vector approach to gene therapy.

"Our aim is to create a one-stop shop for nonviral gene therapy that uses the most potent cargo and safely delivers it to the right tissue with every application,” said Joël

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

More from Business

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.